A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer

In Vivo 2026 Open access

Read full text
Authors: Satoru Nihei, Haruki Ujiie, Kazuki Saito, Tatsuki Ikeda, Junichi Asaka, MIZUNORI YAEGASHI, Koichi Asahi, Kenzo Kudo
DOI: 10.21873/invivo.14210
Cited by: 2

Abstract

Background/Aim: Bevacizumab (Bev) often induces hypertension and proteinuria. Optimal antihypertensive management in this setting remains unclear, and studies comparing angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) are limited. The objective of this study was to compare the effects of the ARB azilsartan and the CCB amlodipine on hypertension and proteinuria. Patients and Methods: Patients with demonstrated systolic/diastolic blood pressure (SBP/DBP) ≥140/90 mmHg during Bev therapy for colorectal cancer were randomly assigned 1:1 to either the azilsartan group or the amlodipine group and were followed up for 18 weeks. The primary outcome was urinary protein-to-creatinine ratio (UPCR). Secondary outcomes included BP changes and achievement of target BP (

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies Chemotherapy-induced cardiotoxicity and mitigation Nausea and vomiting management

Publication details

Journal / source
In Vivo
Publisher
International Institute of Anticancer Research
Volume
40
Issue
1
Pages
465–473
Publication date
1 January 2026
Language
EN